Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Investigating the interactions between mesenchymal stromal cells in the bone marrow & leukemic cells

Eric Solary • 5 May 2023
MDS 2023
Chronic Myelomonocytic Leukemia Leukemia Rare Diseases

Eric Solary, MD, Gustave Roussy Institute, Paris, France, highlights the potential of studying the interactions between bone marrow mesenchymal stromal cells with leukemic cells to identify whether it is feasible and useful to target cells in the bone marrow niche and identify the role of the niche in disease progression. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eric Solary

1:09
Selecting patients with CMML for alloSCT
Eric Solary • 5 May 2023
1:19
The impact of disease heterogeneity on treatment decisions in MDS
Eric Solary • 5 May 2023
0:51
Similarities between the WHO and ICC classifications for MDS & the need to create a unified approach
Eric Solary • 5 May 2023
2:03
The need to identify new treatment strategies in CMML & the potential of targeting inflammation
Eric Solary • 5 May 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals